Decision Rules for Subgroup Selection Based on a Predictive Biomarker

REFERENCES

• Addplan, Inc., an Aptiv Solutions Company . ( 2013 ). ADDPLAN PE Version 6.0 User Manual , Rev. 3 . Cologne , Germany : Aptiv Solutions .
   Google Scholar
• Brannath , W. , Zuber , E. , Branson , M. , Bretz , F. , Gallo , P. , Posch , M. , Racine-Poon , A. ( 2009 ). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology . Statistics in Medicine 28 : 1445 – 1463 .
   PubMed Web of Science ®Google Scholar
• Carroll , K. J. ( 2007 ). Biomarkers in drug development: Friend or foe? A personal reflection gained working within oncology . Pharmaceutical Statistics 6 : 253 – 260 .
   PubMed Web of Science ®Google Scholar
• Dekker , T. J. , Borg , S. T. , Hooijer , G. K. , Meijer , S. L. , Wesseling , J. , Boers , J. E. , Schuuring , E. , Bart , J. , van Gorp , J. , Mesker , W. E. , Kroep , J. R. , Smit , V. T. , van de Vijver , M. J. (2012). Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research 14:R93.
   PubMed Web of Science ®Google Scholar
• Friede , T. , Parsons , N. , Stallard , N. ( 2012 ). A conditional error function approach for subgroup selection in adaptive clinical trials . Statistics in Medicine 31 : 4309 – 4120 .
   PubMed Web of Science ®Google Scholar
• Hung , H. M. J. , Wang , S. J. , O'Neill , R. ( 2011 ). Flexible design clinical trial methodology in regulatory applications . Statistics in Medicine 30 : 1519 – 1527 .
   PubMed Web of Science ®Google Scholar
• Jenkins , M. , Stone , A. , Jennison , C. ( 2011 ). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints . Pharmaceutical Statistics 10 : 347 – 356 .
   PubMed Web of Science ®Google Scholar
• Perez , E. A. , Suman , V. J. , Davidson , N. E. , Martino , S. , Kaufman , P. A. , Lingle , W. L. , Flynn , P. J. , Ingle , J. N. , Visscher , D. , Jenkins , R. B. ( 2006 ). HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial . Journal of Clinical Oncology 24 : 3032 – 3038 .
   PubMed Web of Science ®Google Scholar
• Reddy , J. C. , Reimann , J. D. , Anderson , S. M. , Klein , P. M. ( 2006 ). Concordance between central and local laboratory HER2 testing from a community-based clinical study . Clinical Breast Cancer 7 : 153 – 157 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , O'Neill , R. T. , Hung , H. M. J. ( 2007 ). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset . Pharmaceutical Statistics 6 : 227 – 244 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , Hung , H. M. J. , O'Neill , R. T. ( 2009 ). Adaptive patient enrichment designs in therapeutic trials . Biometrical Journal 51 : 358 – 374 .
   PubMed Web of Science ®Google Scholar
• Wolff , A. C. , Hammond , M. E. , Schwartz , J. N. , Hagerty , K. L. , Allred , D. C. , Cote , R. J. , Dowsett , M. , Fitzgibbons , P. L. , Hanna , W. M. , Langer , A. , McShane , L. M. , Paik , S. , Pegram , M. D. , Perez , E. A. , Press , M. F. , Rhodes , A. , Sturgeon , C. , Taube , S. E. , Tubbs , R. , Vance , G. H. , Van de Vijver , M. J. , Wheeler , T. M. , Hayes , D. F. ( 2007 ). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer . Journal of Clinical Oncology 25 : 118 – 145 .
   PubMed Web of Science ®Google Scholar